drugset / Trial / NCT05504486
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
Phase 4
Withdrawn
Otsuka Pharmaceutical Development & Commercialization, Inc.
H. Lundbeck A/S · collab
NaSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.
Timeline
- Start
- 2022-08-29
- Primary completion
- 2023-03-22
- Completion
- 2023-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexpiprazole | Small molecule | 2 mg | Oral |